VivoSim Labs, Inc.
VivoSim Labs, Inc., a pharmaceutical and biotechnology services company, provides testing of drugs and drug candidates in three-dimensional (3D) human tissue models of liver and intestine. It offers partners liver and intestinal toxicology insights through its new approach methodologies (NAM) models; and bespoke services in the areas of investigational toxicology, mechanism of drug action elucida… Read more
VivoSim Labs, Inc. (VIVS) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.337x
Based on the latest financial reports, VivoSim Labs, Inc. (VIVS) has a cash flow conversion efficiency ratio of -0.337x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.38 Million) by net assets ($7.07 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
VivoSim Labs, Inc. - Cash Flow Conversion Efficiency Trend (2011–2025)
This chart illustrates how VivoSim Labs, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
VivoSim Labs, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of VivoSim Labs, Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Stavely Minerals Ltd
AU:SVY
|
-0.194x |
|
Akora Resources Ltd
AU:AKO
|
-0.058x |
|
Shah Alloys Limited
NSE:SHAHALLOYS
|
1.627x |
|
Carlo Rino Group Bhd
KLSE:0335
|
0.035x |
|
ChowChow Cloud International Holdings Limited
NYSE MKT:CHOW
|
0.044x |
|
CIZZLE BIOTECHN. LS-0001
F:E7F0
|
N/A |
|
Global Oriental Bhd
KLSE:1147
|
-0.038x |
|
Legacy Gold Mines Ltd.
V:LEGY
|
N/A |
Annual Cash Flow Conversion Efficiency for VivoSim Labs, Inc. (2011–2025)
The table below shows the annual cash flow conversion efficiency of VivoSim Labs, Inc. from 2011 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | $10.49 Million | $-9.46 Million | -0.902x | +77.84% |
| 2024-03-31 | $3.60 Million | $-14.65 Million | -4.069x | -402.71% |
| 2023-03-31 | $15.33 Million | $-12.41 Million | -0.809x | -189.28% |
| 2022-03-31 | $30.21 Million | $-8.45 Million | -0.280x | +17.68% |
| 2021-03-31 | $39.20 Million | $-13.32 Million | -0.340x | +39.17% |
| 2020-03-31 | $26.63 Million | $-14.88 Million | -0.559x | +0.45% |
| 2019-03-31 | $36.30 Million | $-20.38 Million | -0.561x | +13.27% |
| 2018-03-31 | $44.59 Million | $-28.86 Million | -0.647x | -38.30% |
| 2017-03-31 | $62.36 Million | $-29.18 Million | -0.468x | +0.91% |
| 2016-03-31 | $62.18 Million | $-29.37 Million | -0.472x | -17.34% |
| 2015-03-31 | $48.70 Million | $-19.60 Million | -0.403x | -24.90% |
| 2014-03-31 | $48.28 Million | $-15.56 Million | -0.322x | -117.63% |
| 2013-03-31 | $-5.30 Million | $-9.69 Million | 1.828x | -89.28% |
| 2011-03-31 | $-6.42K | $-109.42K | 17.052x | -- |